1. Home
  2. ATYR vs HCAT Comparison

ATYR vs HCAT Comparison

Compare ATYR & HCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.73

Market Cap

79.2M

Sector

Health Care

ML Signal

HOLD

Logo Health Catalyst Inc

HCAT

Health Catalyst Inc

HOLD

Current Price

$2.51

Market Cap

174.0M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATYR
HCAT
Founded
2005
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
174.0M
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
ATYR
HCAT
Price
$0.73
$2.51
Analyst Decision
Buy
Hold
Analyst Count
6
11
Target Price
$8.75
$4.30
AVG Volume (30 Days)
2.0M
631.1K
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$190,000.00
$316,063,000.00
Revenue This Year
N/A
$3.23
Revenue Next Year
$18,728.88
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
4.63
52 Week Low
$0.64
$2.02
52 Week High
$7.29
$7.65

Technical Indicators

Market Signals
Indicator
ATYR
HCAT
Relative Strength Index (RSI) 43.88 48.87
Support Level $0.70 $2.32
Resistance Level $0.76 $2.49
Average True Range (ATR) 0.04 0.12
MACD 0.01 0.01
Stochastic Oscillator 36.80 51.35

Price Performance

Historical Comparison
ATYR
HCAT

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About HCAT Health Catalyst Inc

Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.

Share on Social Networks: